Table 4.
Outcome Measures of Effectiveness in Ten Subjects Switched from Olanzapine to Clozapine During the 12-Week Open-Label Extension Study
| Measure | Week 12 | Week 24a | t | df | p | Effect size (d) |
|---|---|---|---|---|---|---|
| BPRSb | ||||||
| Total | 42.7 (13.81) | 30.4 (11.01) | 3.54 | 9 | 0.006 | 0.18 |
| Psychosis cluster | 10.7 (4.61) | 8.3 (4.21) | 2.09 | 9 | 0.07 | 0.58 |
| SANS total scorec | 9.2 (4.21) | 6.0 (3.61) | 3.53 | 9 | 0.006 | 0.97 |
| CGId | ||||||
| Improvement | 3.7 (1.31) | 2.1 (0.31) | 3.54 | 9 | 0.006 | 1.74 |
| Severity of Illness | 4.3 (1.1) | 3.0 (1.1) | 3.88 | 9 | 0.004 | 0.48 |
| CGASe | 36.2 (17.21) | 54.0 (17.61) | −2.59 | 8 | 0.03 | 0.36 |
All data are presented as mean (standard deviation). Effect sizes calculated as d = (Mean1 – Mean2)/pooled standard deviation.
a
Or trial end point.
b
Brief Psychiatric Ratings Scale.
c
Scale for the Assessment of Negative Symptoms. Total Score = sum of global scores (affective flattening, alogia, avolition, asociality-anhedonia).
d
Clinical Global Impressions—Improvement Scale.
e
Children's Global Assessment Scale.